Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy (MIT-E)
2020-002100-39Phase 2Suspended
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Mitochondriopathy and epilepsy comparing Vatiquinone with Placebo (2 arms). Primary endpoint: Percent change in observable motor seizure frequency. Started Feb 2021; status: suspended.
02
Drugs
vatiquinone
03
Conditions
Mitochondriopathyepilepsy
Beyond the preview
Go deeper on 2020-002100-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002100-39.